Despite the continuing impact of the global COVID-19 pandemic on health systems, we were able to ensure the continuation of community-based interventions that enabled more than 15 million patients to access quality assured treatment for malaria, diarrhoea, and pneumonia between April 2021 and March 2022. We are incredibly grateful to the thousands of individuals who have donated to Malaria Consortium in this period. Thanks to our supporters’ generosity we saw a doubling of income through individual philanthropy (£1.08m compared with £0.45m in 202/21), supporting our mission to save lives and improve health in Africa and Asia.
In 2021/22 we received total income of £84.4 million, an increase of £16.5 million (+24 percent) on the previous year. The increase in income was primarily due to a £10 million (34 percent) increase in investment to expand our seasonal malaria chemoprevention (SMC) programme in Nigeria, Togo, Mozambique, and Uganda and enabling us to reach over 20 million children under the age of five years with preventative malaria treatment across six countries.
This reporting period, we changed how we recorded advance income received to deliver our SMC programme in years outside of the reporting period, to better reflect funding allocated to future programmatic delivery. Previously recognised as restricted reserves, this income is now accounted for as deferred income (liability). The prior year comparatives have been restated to reflect this (further details in note 19 of the annual accounts).
Over 95 percent of Malaria Consortium’s total expenditure was spent on programmatic activities across Africa and Asia, the remaining (4.5 percent) was spent on the vital support required to keep our operations running and raising future income to sustain our work.
« Back to Publications